66 results about "Interstitial lung disease" patented technology

The invention provides an ELISA (Enzyme Linked Immunosorbent Assay) kit for detecting an anti-MDA5 antibody and a preparation method of the ELISA kit. According to the kit, full-length human MDA5 protein (1025 amino acids) expressed by a cell-free protein expression system under the low-temperature condition of 22 DEG C is adopted as a coating antigen, and a disulfide bond enhancer E6820 is added into the system to promote correct folding of the protein. The kit comprises a microwell plate coated with a full-length MDA5 antigen, an enzyme-labeled anti-human IgG secondary antibody, a standard substance with the concentration range of 1-243 ng / mL, a chromogenic substrate and an optimized confining liquid system. The invention solves the problem of insufficient sensitivity caused by the use of fragment antigens in the prior art, and can be used for early diagnosis and illness monitoring of dermatomyositis-related interstitial lung diseases.

A computer implemented method for quantifying and predicting the progression of interstitial lung disease is disclosed herein. The method comprises obtaining at least one image based on a scan of at least a part of a patient's lung, segmenting the image to obtain a lung mask defining the periphery of the lung and to identify structures within the lung mask, and applying a weighting to the identified structures based on the relative position of the structures relative to the lung periphery to obtain a weighted score. The method may then comprise quantifying the extent of interstitial lung disease, and / or predicting the progression of interstitial lung disease, based on the weighted score.

The present invention provides compounds of formula I for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonosis, nonalcoholic steatohepatitis (NASH), interstitial lung disease (ILD), and idiopathic pulmonary fibrosis (IPF). JPEG2026504613000125.jpg8493 (in the formula, R 1 , R 2 , R 3 , R 4 , A, D, E, G, J, K, and L are as defined in claim 1), and prodrugs, deuterated analogs, and pharmaceutically acceptable salts thereof.

A medicament for treatment or prevention of interstitial lung disease, and of a disease or symptom accompanied by systemic sclerosis in a subject, the medicament comprising, as an effective ingredient, 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt or co-crystal thereof.

The invention relates to the technical field of medical informatics, and provides an interstitial lung disease HRCT image analysis method and system based on artificial intelligence. The method comprises the following steps: performing pulmonary parenchyma segmentation processing on an input HRCT image to obtain a pulmonary parenchyma region; performing multi-category lesion segmentation on the pulmonary parenchyma region to obtain a segmentation mask; performing quantitative calculation on lesion distribution characteristics according to the segmentation mask to obtain lesion distribution parameters; and carrying out image mode classification according to the segmentation mask and the lesion distribution parameters to obtain a classification result. According to the method, the efficiency and precision of HRCT image analysis are improved, and the application range of HRCT image analysis is expanded.

The invention relates to a crystal form of a compound shown as a formula I or a pharmaceutically acceptable salt thereof and a preparation method of the crystal form of the compound shown as the formula I or the pharmaceutically acceptable salt thereof. The compound of the formula I or the pharmaceutically acceptable salt thereof is used for treating cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary arterial hypertension (WHO levels I, II, III, IV), angina pectoris, thrombus, restenosis, myocardial infarction, stroke, cardiac insufficiency, fibrosis, pulmonary hyperplasia, erectile dysfunction, asthma, chronic kidney disease, diabetes, and the like. The composition can be used for treating liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, cystic fibrosis or interstitial lung disease.

To provide a type C natriuretic peptide and a method for treating acute lung injury. [Solution] This disclosure relates to the treatment of lung, liver, and / or kidney disorders by administering therapeutically effective doses of (ultra)long-acting C-type natriuretic peptide (CNP), CNP derivatives, (ultra)long-acting CNP derivatives, or (ultra)long-acting CNP receptor (NPRB) agonists to subjects in need. This disclosure also relates to the treatment of non-cardiovascular causes of hypoxia, elevated inflammatory cell levels in the lungs, pulmonary edema, sepsis, bacteremia, fibrosis in general, and / or interstitial lung disease using these.

The invention relates to new proline derivatives of formula (I) as cGAS inhibitors,whereinwherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compoundsfor the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).

The invention relates to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for treating interstitial lung disease with fibrosis and a preparation method and application thereof.The traditional Chinese medicine composition is prepared from, by weight, 5-15 parts of ginseng, 8-15 parts of radix asparagi, 10-20 parts of radix rehmanniae recen, 15-25 parts of astragalus membranaceus, 5-15 parts of schisandra chinensis, 15-25 parts of honey-fried radix asteris, 15-25 parts of honey-fried flos farfarae, 8-15 parts of curcuma zedoary, 8-15 parts of peach kernels and 8-15 parts of herba epimedii. , 15-30 parts of semen lepidii, 10-20 parts of fructus liquidambaris, and 10-20 parts of semen sinapis. The traditional Chinese medicine composition provided by the invention has the effects of strengthening vitality, reducing phlegm, activating blood, removing blood stasis and dredging collaterals, and can improve clinical symptoms of patients with interstitial lung diseases and fibrosis, improve life quality and delay disease progression.

The invention discloses a construction method of an endothelial cell knockout Cdc42 gene aggravated bleomycin induced pulmonary fibrosis mouse model, which comprises the following steps of: mating a Cdc42 gene conditional knockout mouse with a mouse (Tie2-CreER) of which the endothelial cell specifically expresses tamoxifen induced Cre recombinase to obtain a double-transgenic mouse (Cdc42fl / fl-Tie2-CreER); the Cdc42 gene is specifically knocked out in vascular endothelial cells under the induction of tamoxifen, and then pulmonary fibrosis is induced by subcutaneous injection of bleomycin. The model shows aggravated pulmonary fibrosis phenotypes, including collagen deposition increase, alveolar structure damage and fibrosis-related protein expression up-regulation, and is high in construction success rate and good in repeatability. The invention also provides an application of the model in research of systemic sclerosis related interstitial lung disease pathogenesis and screening of anti-pulmonary fibrosis drugs, and an application of the Cdc42 gene as a drug target, and provides an accurate and reliable tool for pulmonary fibrosis research.

Compositions and methods for treating chronic obstructive pulmonary disease, interstitial lung disease, asthma, bronchitis, pneumonia, cystic fibrosis, pulmonary edema, sarcoidosis, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, acute respiratory distress syndrome, and respiratory syncytial virus in a patient are presented. Embodiments of the composition include a combination of diethylcarbamazine (DEC) and a prostacyclin analogue, such as Beraprost, Beraprost sodium, Iloprost, Treprostinil, Treprostinil Palmitil, and Cicaprost. Other embodiments include fluvoxamine and / or a phosphodiesterase (PDE) inhibitor. Some embodiments of the composition are in the form of an aerosol, include a propellent, or are in an inhalation delivery device.

The present disclosure relates to methods of treating interstitial lung disease by administering (1S,3S)-3-((2-methyl-6-(1-methyl-5-(((methyl(propyl)carbamoyl)-oxy)methyl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)oxy)cyclohexane-1-carboxylic acid (an LPA1 antagonist).

The disclosure describes methods and compositions for reducing the level or activity of metabotropic glutamate receptor 5 (mGluR5) or / and cannabinoid receptor 1 (CB1R) for the treatment of fibrotic disorders such as pulmonary fibrotic disorders (e.g., fibrosing interstitial lung discases). In some embodiments, a mGluR5 antagonist or / and a CB1R antagonist (c.g., a peripheral CB1R antagonist) is / are used to treat a fibrotic disorder such as a pulmonary fibrotic disorder (e.g., a fibrosing interstitial lung disease).

The application belongs to the technical field of image recognition, and discloses a weakly supervised interstitial lung disease lesion recognition method based on multiple example learning, which comprises the following steps: step 1: acquiring CT image samples; step 2: selecting part of the CT images, and manually labeling the lung parenchyma in the images; step 3: establishing a lung parenchyma segmentation model through a saliency segmentation algorithm, inputting the manually labeled CT image samples to perform training and testing, and obtaining a trained lung parenchyma segmentation model; step 4: training a lesion recognition model using a multiple example learning algorithm; step 5: acquiring a to-be-recognized CT image sample, inputting the lung parenchyma segmentation model to perform segmentation, and then inputting the segmented data sample into the lesion recognition model to obtain a lesion position. The application can realize the visual labeling of interstitial lung disease through a small amount of labeling, and greatly improves the recognition efficiency.

The objective is to provide methods for treating interstitial lung disease, mitigating lung function decline in individuals with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in individuals suffering from ILD. [Solution] A method for treating pulmonary hypertension caused by a condition selected from chronic lung disease, hypoxia, and combinations thereof, comprising administering an effective amount of treprostinil, its prodrug, or a pharmaceutically acceptable salt thereof to a subject with pulmonary hypertension caused by a condition selected from chronic lung disease, hypoxia, and combinations thereof.

The invention belongs to the technical field of biology, and particularly relates to application of an Mgst2 gene serving as a target to preparation of a product for treating rheumatoid arthritis related interstitial lung diseases. According to the invention, it is found for the first time that Mgst2 can be used as a biomarker for treatment of rheumatoid arthritis related interstitial lung diseases, targeted knock-down is carried out on Mgst2 in neutrophils through an AAV9-shRNA vector (AAV9-shRNA-Mgst2) driven by a Cd11b promoter, and lung lesion progress can be effectively relieved by inhibiting NET formation. The Mgst2 inhibitor provided by the invention can directly intervene in the occurrence and development process of diseases from a molecular level, and has the advantages of accurate effect, remarkable curative effect, low side effect and the like. Compared with a traditional non-specific treatment mode, the product takes effect only aiming at specific molecular targets, damage to normal cells and tissues is remarkably reduced, and therefore the risk of toxic and side effects is reduced.

A traditional Chinese medicine composition and a traditional Chinese medicine decoction are used for preventing and / or treating interstitial lung disease. The traditional Chinese medicine composition includes: 25-35 parts of Astragali Radix, 15-25 parts of Codonopsis Radix, 10-15 parts of Atractylodis Macrocephalae Rhizoma, 10-20 parts of Poria, 10-15 parts of Armeniacae Semen Amarum, 10-15 parts of Platycodonis Radix, 10-20 parts of Salviae Miltiorrhizae Radix et Rhizoma, 10-20 parts of Chuanxiong Rhizoma, 10-15 parts of Angelicae Sinensis Radix, 4-10 parts of Schisandrae Chinensis Fructus, and 5-12 parts of Glycyrrhizae Radix et Rhizoma. These ingredients together have the effects of strengthening and replenishing (the spleen and the lung), activating blood and dissolving stasis, and relieving cough and asthma, thereby preventing and / or treating interstitial lung disease.

Methods of treating of interstitial lung disease, reducing pulmonary function decline in a subject with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in a subject suffering from ILD are provided, wherein the methods include administration of treprostinil.

This disclosure provides a dry powder composition of treprostol prodrug and a method of treating pulmonary hypertension (e.g., pulmonary arterial hypertension or PH associated with interstitial lung disease) in patients in need using said dry powder composition. The dry powder composition comprises: (a) about 0.5 wt% to about 5 wt% of a compound, its stereoisomers, or a pharmaceutically acceptable salt thereof; (b) about 10 wt% to about 61 wt% of leucine; and the remainder is (c) a sugar selected from the group consisting of trehalose and mannitol. The total of (a), (b), and (c) is 100 wt%, and R1 is tetradecyl, pentadecyl, hexadecyl, heptadecanyl, or octadecyl. The method of treating PH comprises administering an effective amount of the dry powder composition to the lungs of the patient by inhalation via a dry powder inhaler during an administration period.

There is provided herein a compound of formula I,wherein R1, R2, R3 Y1, Y2, Y3, Y4, R4, R5 and R6 are as defined herein, which compounds are useful in the treatment of autoimmune and / or fibrotic diseases, including interstitial lung diseases, such as idiopathic pulmonary fibrosis and sarcoidosis.

This paper discloses a computer-implemented method for quantifying and predicting the progression of interstitial lung disease. The method includes obtaining at least one image based on a scan of at least a portion of a patient's lungs, segmenting the image to obtain a lung mask defining the lung margin, identifying structures within the lung mask, and weighting the identified structures based on their relative positions to the lung margin to obtain a weighted score. The method can then include quantifying the degree of interstitial lung disease based on the weighted score, and / or predicting the progression of interstitial lung disease.

Disclosed herein are methods of stabilizing or improving lung function in subjects with an interstitial lung disease (ILD) by orally administering a daily amount of between 1600 mg and 2500 mg deupirfenidone. Also disclosed are methods of dose escalation for initial titration, methods of reducing the incidence of emerging adverse events, and methods of directly transitioning patients from other drugs to deupirfenidone without titration.

The present disclosure relates to a method of treating interstitial lung disease by administering Compound A to a subject at one or more daily doses lower than the standard daily dose during a dose escalation treatment period, followed by escalating the dose to the standard daily dose of Compound A, wherein the standard daily dose is the equivalent of about 240 mg / day of Compound A or a pharmaceutically acceptable salt thereof.

In certain aspects, the present disclosure relates to methods of treating systemic sclerosis (SSc) using TβRII antagonists comprising a heterologous domain and a truncated, ligand-binding portion of the extracellular domain of TβRII polypeptide useful to selectively antagonize a TβRII ligand. The disclosure further provides methods for treating one or more complications of SSc, including interstitial lung disease (ILD), with TβRII antagonists of the present disclosure.

A medicament for treatment or prevention of interstitial lung disease, and of a disease or symptom accompanied by systemic sclerosis in a subject includes, as an effective ingredient, 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt or co-crystal thereof.

Compound (A) Described herein is the LPA1 antagonist (1S,3S)-3-((2-methyl-6-(1-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)oxy)cyclohexane-1-carboxylic acid, including crystalline forms of TIFF2025542317000009.tif31165 and preparations thereof. Pharmaceutical compositions containing the LPA1 antagonists, and methods of using the LPA1 antagonists for the treatment of interstitial lung disease, are also disclosed.

The present invention provides a combination therapy comprising a TNF inhibitor compound and a mitochondrial complex I modulator (MCIM) compound that is useful in the medical field of inflammatory and progressive disorders such as RA, IBD, idiopathic pulmonary fibrosis, interstitial lung disease, and MS.

The present disclosure features chemical entities (e.g., compounds or pharmaceutically acceptable salts thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA-related kinase 7 (NEK7). The chemical entities are useful, for example, in treating subjects having one or more conditions or diseases associated with NLRP3 inflammasome activation (e.g., human subjects). The conditions or diseases include, but are not limited to, autoinflammatory and autoimmune conditions (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic conditions (e.g., pericarditis, atherosclerosis, type 2 diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, diabetes mellitus, and the like). ), fibrotic disorders (e.g., interstitial lung disease, chronic kidney disease), hematological disorders (e.g., inflammatory anemia), and ocular disorders (e.g., macular degeneration). In embodiments, although not desired to be constrained theoretically, the chemical entities described herein are believed to directly target (e.g., bind directly) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. The disclosure also features compositions containing the entities as well as methods of using and making the entities.

Methods of treating of interstitial lung disease, reducing pulmonary function decline in a subject with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in a subject suffering from ILD are provided, wherein the methods include administration of treprostinil.